Focusing on the key challenges Decision-making & drug development Peter Hertzman Paul Miller.

Slides:



Advertisements
Similar presentations
Matthew M. Riggs, Ph.D. metrum research group LLC
Advertisements

Contribution of Economics to Operational Research for Evaluation of Scaling Up Access to HIV Care & Treatment in Developing Countries Presentation by Pr.
1 WORKSHOP 4: KEY COMMENTS FROM THE PANEL DISCUSSION The 3rd Kitasato University - Harvard School of Public Health Symposium Wednesday October 2nd - Thursday.
PHARMACOECONOMICS THE ROLE OF PHARMACOECONOMICS FROM THE PHARMACOECONOMICS ON THE INTERNET ®SERIES © Paul C Langley, 2004 Maimon Research LLC.
The Statisticians Role in Pharmaceutical Development
The Influence of HTA in Shaping Drug Development: Investment Implications Steven J. Romano, MD Senior Vice President and Head, Primary Care Medicines Development.
STATISTICS DEFINITION AND MEANING
The evolving role of real-world evidence to support policy and practice CADTH 2015.
Optimal Drug Development Programs and Efficient Licensing and Reimbursement Regimens Neil Hawkins Karl Claxton CENTRE FOR HEALTH ECONOMICS.
Chapter 14 Assessing the Value of IT. Traditional Financial Approaches  ROI – Return on Investments Each area is considered an investment center ROI.
S TRUCTURAL B IOINFORMATICS. A subset of Bioinformatics concerned with the of biological structures - proteins, DNA, RNA, ligands etc. It is the first.
International Experience in Pharmaceutical Services for Promoting Access to Medicines: Canada, Cuba, England, Mexico International Seminar on the Challenges.
Industrial Organization Economists have developed a branch of economic analysis called Industrial Organization to trace the relationship between the structure.
1Carl-Fredrik Burman, 11 Nov 2008 RSS / MRC / NIHR HTA Futility Meeting Futility stopping Carl-Fredrik Burman, PhD Statistical Science Director AstraZeneca.
What SMS means for an Operator’s relationship with the CAA
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
Portfolio Risk Analysis Kimber Hardy November 2012.
Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.
Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.
Drug Pricing in Canada Victoria Brown, Anureet Sohi, Lisa Weger SPHA 511.
Michelle Boudreau, Vice President, Private Markets, March 11, 2015 Presentation to CADA.
REGISTRATION OF MEDICINES & PROGRESS WITH RESTRUCTURING THE MCC 1.
© Peter-Jan Engelen Handling Complex Decisions in the Development of New Drugs in Pharmaceutical Firms FUR XII, LUISS, Roma, Italy, June 2006 Cassimon,
Stages of drug development
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
The Nature and Scope of Managerial Economics
MANAGERIAL ECONOMICS.
Economic evaluation of health programmes Department of Epidemiology, Biostatistics and Occupational Health Class no. 16: Economic Evaluation using Decision.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Pharmaceutical Epistemology Jim Golden, Ph.D. Global Lead, Healthcare Data Analytics Accenture
Figure 4.1 NEW PRODUCT DEVELOPMENT PROCESS Finance Corporate strategy and portfolio decisions Regulatory affairs Marketing and sales + market research.
The Infectious Diseases Institute Kampala, Uganda InfoPoverty World Conference United Nations InfoPoverty World Conference United Nations Robert L. Mallett.
1 Value Assessment of Development-Stage Assets Pharmaceutical Products, Medical Devices, and Related Intellectual Property Frank S. Castellana, M.D., Eng.Sc.D.
PharmaSim COMPETITIVE STRATEGY
Stefan Franzén Introduction to clinical trials.
International Business: Actions Entry mode (I)
Shifting resources: disinvestment and re-investment Craig Mitton, PhD Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research.
Managing Medical R&D Defining and Realizing Clinical and Commercial Value David J. Wierz Senior Director Commercial Investment & Pricing Strategy Wyeth-Ayerst.
ISPOR POLAND CHAPTER Polish Society of Pharmacoeconomics (PTFe )
1 Vaccine Development: From the Lab to the Clinic Jim Tartaglia, PhD Vice-President, R & D Sanofi Pasteur AIDS Vaccine 2011 Bangkok, Thailand September.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
HTA cooperation in the EU EPF workshop Jérôme Boehm 18 May 2010.
Medicine Differentiation Analytics Process Presentation to…. Date….
The Use of Scientific Advisory Boards An Invaluable Tool in Drug Development Dr Robert Miller Chief Medical Officer Fulcrum Pharma Developments 19 th Annual.
Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.
Developing medicines for the future and why it is challenging Angela Milne.
Managing Risk Through Pharmaceutical Product Life Cycles Hosted and Sponsored by Novartis Institutes for Biomedical Research for HBA Boston Chapter February.
Current Challenges and Future Developments in HTA in the UK Frances Macdonald, 23 rd September 2008 (A personal, Industry View)
DETERMINE Working document # 4 'Economic arguments for addressing social determinants of health inequalities' December 2009 Owen Metcalfe & Teresa Lavin.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health (BMG) The use of.
Privacy Symposium / HIPAA Summit
Is the conscientious explicit and judicious use of current best evidence in making decision about the care of the individual patient (Dr. David Sackett)
Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.
A quick overview into current uses of the emerging big data technologies within the industry Basel Life Sciences Forum 18JUN2015 Rob Walls EU Regional.
Health Technology Assessment for Pharmaceuticals and New Medical Technologies - Where are we now? The industry perspective Jenny Hughes, Director, Vaccines.
Balancing revenues and costs for orphan drugs: a case study Aidan Hollis University of Calgary: Department of Economics and O’Brien Institute of Public.
Gwendolyn Ryals, Look at Me Artwork from The Creative Center Janey Shin, Director, Real World Evidence Government Affairs and Market Access CADTH Symposium.
Regulatory and Reimbursement Harmonization An Industry Perspective Adrian Griffin | April 2016.
Andy Passey September 23rd 2003 Advanced Wound Management in Europe: Market Overview and Critical Success Factors © 2003 Frost & Sullivan. All rights reserved.
The process of drug development. Drug development 0,8 – 1 mld. USD.
Clinical Trials.
SAMBa ITT – Portfolio Management Alun Bedding SAMBa ITT 4 Strictly Confidential 31 st May 2016.
Drug Development Process Stages involved in Regulating Drugs
Cost effectiveness Analysis: Valuing Health; Valuing Research!
Patient Focused Drug Development An FDA Perspective
Regulatory perspective
MIDD: Perspectives and Possibilities
EUnetHTA Assembly May 2018.
Presentation transcript:

Focusing on the key challenges Decision-making & drug development Peter Hertzman Paul Miller

Rationale 1.From societal perspective the case for bayesian analysis (BA) to inform adoption decisions for new technologies is strong 2.From an individual firm’s perspective there may be a lot more (other) reasons to use bayesian analysis 3.(2) may be the best foundation for (1) benefits (internal to the firm) during drug development will provide incentives to invest (promote) in BA this will impact societal HTA

Q1. What are the objectives of pharmacoeconomics?

SalesRevenue 1 st Objective of PharmacoEconomics PRICE VOLUME

Approval 2 nd Objective of PharmacoEconomics REIMBURSEMENT FORMULARY LISTING PRICING APPROVAL (PRODUCT LICENSING)

3 rd Objective of PharmacoEconomics R&DCosts Assist internal decision-making and resource allocation during drug development

R&D Costs Sales Revenue Approval

Q2. Which tools do we use?

The Economist The Phase III Trial

Q3. Which tools could we use?

Bayesian Analysis Longitudinal Databases CTS Conjoint AnalysisQoL Assessment Contingent Valuation Economic Modelling PROs Value of InformationThreshold Analysis

So, how can we deliver more? 1.Exploit methodological advances in economic evaluation and decision theory 2.Integrate these into a broader range of activities 3.Review the timing of these activities in the product lifecycle

Gathering information Modelling Predicting Optimizing decisions Benefits Synthesis of Evidence Quantifying Uncertainty

Need for Bayesian Analysis (Regulator’s perspective) To synthesise all available evidence in an explicitly quantitative analysis To quantify uncertainty To understand the marginal value of more information –Weigh contribution of more information (certainty) vs. Opportunity costs of delayed adoption Adopt in awareness of level of uncertainty; or Adopt, retricted to more certain domains (populations) Reject, value of more information > cost to society

Need for Bayesian Analysis (Pharma perspective) Where ’regulator’ requires it! Eg.UK NICE –Still not viewed as a real barrier to market access What proportion of global sales will be affected? –“only one (small) market” argument Does Pharma need to change the way it works? Weak incentive: “the stick” is not perceived as big enough! Carrots may be more effective! – scope for bayesian analysis in drug development process is large

Drug Development Process 1.Test 5, ,000 compounds, to identify candidates for further development 2.Send approx. 250 for pre-clinical testing 3.Enter approx. 5 into: –Phase 1 trials (<100 healthy volunteers, to determine safety and dosage). If successful: –Phase 2 trials (<300 volunteers, to test for efficacy and side effects). If successful: –Phase 3 trials (> 1,000 volunteers, to monitor longer-term use and adverse reactions). If successful: 4.Approval of the new drug: license –10+ years after identification for development –Cost incurred per NCE = $ 600 million 5.Pricing & Reimbursement discussions

Observations Process is long, costly and risky! Highly regulated industry: –Gather drug profile information for regulatory authorities to make decisions (license, price, reimburse) –Some information then used for promotional claims to persuade customers to make decisions (also regulated)

Two fundamental questions 1.Which projects do we invest in? 2.How do we maximise the efficiency of the projects we do choose? (i.e allocative and technical efficiency issues)

uncertainty time Select candidate drugs to develop Clinical trial design? NICE REVIEW Clinical indication? Stop/go? I IIIII P&R strategy? Decisions

PreclinicalPhase IPhase IIPhase IIIPhase IV LAUNCH Pilot outcomes & resource use questionnaire Collect cost & outcome data Populate economic models Inform external decision-makers

PreclinicalPhase IPhase IIPhase IIIPhase IV LAUNCH Pilot outcomes & resource use questionnaire Collect cost & outcome data Populate economic models Inform external decision-makers Ongoing evaluation in ‘real world’ Scenario Modelling: estimate c/e ranges estimate budget impact determine price bands Inform internal decisions: 1. Project management 2. Portfolio management

Early = data vaccum? Not necessarily… Use what we do know! –PK & PD data, CTS, predict drug profile –Disease knowledge & Epidemiology –Market knowledge –Competitor knowledge –Regulatory requirements

Project Management Clinical development programme design: optimising decisions, eg. Number and timing of decision points Speed of development Order of trials Dose Sample size Sample selection About efficiency in trial design Optimise what? Intermediate or final endpoints?

Portfolio Management

References: Burman CF, Senn S. Examples of option values in drug development. Pharmaceut Statist. 2003;2: Poland B, Wada R. Combining drug-disease and economic modelling to inform drug development decisions. Drug Discovery Today 2001: 6(22): Shih Y-C T. Bayesian approach in pharmacoeconomics: relevance to decision-makers. Expert Rev. Pharmacoeconomics Outcomes Res. 2003; 3(3):